Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10012179 | 0.81 | ACHE (0.46) | HSD17B1HSD17B2ACHESIGMAR1RECQL | |
| SCHEMBL28308085 | 0.81 | ACHE (0.39) | ACHESIGMAR1RECQLCYP3A4TDP1 | |
| SCHEMBL7541402 | 0.79 | TDP1 (0.47) | HSD17B1HSD17B2ACHESIGMAR1CYP3A4 | |
| SCHEMBL2584789 | 0.79 | ACHE (0.44) | HSD17B1HSD17B2ACHESIGMAR1CYP3A4 | |
| M-Xylene SCHEMBL29191897 | 0.78 | ACHE (0.60) | ACHETDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL4645028 | 0.78 | ERN1 (0.34) | CYP3A4TDP1ALDH1A1 | |
| SCHEMBL2967403 | 0.78 | ACHE (0.42) | HSD17B1HSD17B2ACHESIGMAR1RECQL | |
| SCHEMBL7370235 | 0.78 | CYP3A4 (0.42) | SIGMAR1RECQLCYP3A4TDP1ALDH1A1 | |
| SCHEMBL3926709 | 0.78 | ALDH1A1 (0.45) | TDP1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2088529 | 0.78 | HTR3E (0.49) | HSD17B1HSD17B2TDP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143645-A | Industrial method for synthesizing tolnaftate by one-pot method | 内蒙古幸源新材料科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10918627-B2 | Convergent and enantioselective total synthesis of Communesin analogs | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-16 | — | — | US | disclosed |
| CN-108774147-B | N-aryl formamide prepared by taking bromodifluoroacetic acid ethyl ester as formylation reagent | 温州大学 | 2021-01-08 | — | — | CN | disclosed |
| CN-108774147-A | A kind of N- aryl carboxamides prepared as formylation reagent using bromo difluoro acetate ethyl ester | 温州大学 | 2018-11-09 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090215851-A1 | Method of Preparing a Porphyrin Derivative, a Porphyrin Derivative, Use of Said Porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative | PHOTOBIOCHEM N.V. (NL) | 2009-08-27 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1866309-A1 | A METHOD OF PREPARING A PORPHYRIN DERIVATIVE, A PORPHYRIN DERIVATIVE, USE OF SAID PORPHYRIN | Photobiochem N.V. (NL) | 2007-12-19 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2006096053-A1 | A METHOD OF PREPARING A PORPHYRIN DERIVATIVE, A PORPHYRIN DERIVATIVE, USE OF SAID PORPHYRIN | PHOTOBIOCHEM N.V. (NL) | 2006-09-14 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-1991011448-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215851-A1 | Method of Preparing a Porphyrin Derivative, a Porphyrin Derivative, Use of Said Porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative | CYP3A43, CYP3A4, ALAD | HSD17B1 2928/4885HSD17B2 2696/4885ACHE 1496/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HSD17B1 225/4885HSD17B2 237/4885ACHE 4670/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HSD17B1 384/4885HSD17B2 314/4885ACHE 4734/4885 |
| US-10918627-B2 | Convergent and enantioselective total synthesis of Communesin analogs | CRHR1, NTSR1, CRH | HSD17B1 3171/4885HSD17B2 3657/4885ACHE 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.